Kupka R W, Nolen W A, Altshuler L L, Denicoff K D, Frye M A, Leverich G S, Keck P E, McElroy S L, Rush A J, Suppes T, Post R M
Altrecht Centre for Mental Health Care and University Medical Centre Utrecht, The Netherlands.
Br J Psychiatry Suppl. 2001 Jun;41:s177-83.
The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness.
To give a preliminary summary of emerging findings in these areas.
Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description.
The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients.
The SFBN provides important new data for the understanding and treatment of bipolar disorder.
斯坦利基金会双相情感障碍网络（SFBN）评估双相情感障碍的治疗方法、病程以及反应的临床和神经生物学标志物。
对这些领域的新发现进行初步总结。
使用已确立的以及可能具有抗躁狂、抗抑郁和心境稳定作用的药物进行的研究，范围从开放病例系列到双盲随机临床试验，并采用相同的核心评估方法，从而优化结果的可比性。美国国立精神卫生研究所生命图表法是回顾性和前瞻性纵向疾病描述的核心工具。
首批入组患者表现出相当程度的既往和当前症状、精神共病以及功能损害。遗传因素和早期环境因素均与更严重的病程相关。使用奥氮平、拉莫三嗪、加巴喷丁或托吡酯作为附加治疗的开放病例系列显示，这些药物在难治性患者中具有不同的疗效谱。
SFBN为双相情感障碍的理解和治疗提供了重要的新数据。
